Maviret
(glecaprevir/pibrentasvir) AbbVie

With nil changes on composition or indication, recommended Maviret treatment duration for treatment-naïve GT3 cirrhotic patients has been shortened to 8 weeks.

Composition:
• Available in film-coated tablet with each contains 100 mg glecaprevir and 40 mg pibrentasvir for oral administration

Indication:
• For the treatment of chronic hepatitis C virus infection in adults and in adolescents aged 12 to <18 years 

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.
The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.